scholarly journals Methotrexate-Loaded Nanostructured Lipid Carrier Gel Alleviates Imiquimod-Induced Psoriasis by Moderating Inflammation: Formulation, Optimization, Characterization, In-Vitro and In-Vivo Studies

2020 ◽  
Vol Volume 15 ◽  
pp. 4763-4778
Author(s):  
Yogeeta O Agrawal ◽  
Umesh B Mahajan ◽  
Hitendra S Mahajan ◽  
Shreesh Ojha
2017 ◽  
Vol 523 (1) ◽  
pp. 398-409 ◽  
Author(s):  
Iqbal Ahmad ◽  
Sohail Akhter ◽  
Mohammed Anwar ◽  
Sobiya Zafar ◽  
Rakesh Kumar Sharma ◽  
...  

2020 ◽  
Vol 13 ◽  
Author(s):  
Ankita Dadwal ◽  
Neeraj Mishra ◽  
Raj Kumar Narang

Background: Psoriasis is an autoimmune disease of the skin with lapsing episodes of hyperkeratosis, irritation, and inflammation. Numerous traditional and novel drug delivery systems have been used for better penetration through psoriatic barrier cells and also for retention in the skin. As there is no effective remedy for better penetration and retention is there because of the absence of an ideal carrier for effective and safe delivery of antipsoriatic drugs. Objectives: The main objective of this project is to develop Squalene integrated NLC based carbopol 940 gel to create a local drug depot in skin for improved efficacy against psoriasis. Methods: Homogenization method is used for the formulation of Nanostructured Lipid Carrier and were characterized on the basis of size, entrapment efficiency, polydispersity index (PDI), viscosity, spreadability, DSC, zeta potential, % in vitro release, in vitro skin permeation and retention studies, physical storage stability studies and in vivo studies can use other alternative models for induction of psoriasis by severe redness, swelling macroscopically and microvascular dilation edema lasting for 10 days. Further histopathology study was done to basses of changes in the skin. Conclusion: The optimized formulation of nanostructured lipid carrier-based gel has shown significant sustained release of clobetasol propionate. Further, this formulation has also shown retention in skin because of squalene as it is sebum derived lipid show affinity towards the sebaceous gland.


2015 ◽  
pp. 633 ◽  
Author(s):  
Kaoxiang Sun ◽  
Zheng Wang ◽  
Hongjie Mu ◽  
Pengkai Ma ◽  
Shengnan Lian ◽  
...  

2001 ◽  
Vol 5 (8) ◽  
pp. 645-651
Author(s):  
M. Peeva ◽  
M. Shopova ◽  
U. Michelsen ◽  
D. Wöhrle ◽  
G. Petrov ◽  
...  
Keyword(s):  

2005 ◽  
Vol 25 (1_suppl) ◽  
pp. S198-S198
Author(s):  
Joseph R Meno ◽  
Thien-son K Nguyen ◽  
Elise M Jensen ◽  
G Alexander West ◽  
Leonid Groysman ◽  
...  

1994 ◽  
Vol 72 (06) ◽  
pp. 942-946 ◽  
Author(s):  
Raffaele Landolfi ◽  
Erica De Candia ◽  
Bianca Rocca ◽  
Giovanni Ciabattoni ◽  
Armando Antinori ◽  
...  

SummarySeveral “in vitro” and “in vivo” studies indicate that heparin administration may affect platelet function. In this study we investigated the effects of prophylactic heparin on thromboxane (Tx)A2 biosynthesis “in vivo”, as assessed by the urinary excretion of major enzymatic metabolites 11-dehydro-TxB2 and 2,3-dinor-TxB2. Twenty-four patients who were candidates for cholecystectomy because of uncomplicated lithiasis were randomly assigned to receive placebo, unfractionated heparin, low molecular weight heparin or unfractionaed heparin plus 100 mg aspirin. Measurements of daily excretion of Tx metabolites were performed before and during the treatment. In the groups assigned to placebo and to low molecular weight heparin there was no statistically significant modification of Tx metabolite excretion while patients receiving unfractionated heparin had a significant increase of both metabolites (11-dehydro-TxB2: 3844 ± 1388 vs 2092 ±777, p <0.05; 2,3-dinor-TxB2: 2737 ± 808 vs 1535 ± 771 pg/mg creatinine, p <0.05). In patients randomized to receive low-dose aspirin plus unfractionated heparin the excretion of the two metabolites was largely suppressed thus suggesting that platelets are the primary source of enhanced thromboxane biosynthesis associated with heparin administration. These data indicate that unfractionated heparin causes platelet activation “in vivo” and suggest that the use of low molecular weight heparin may avoid this complication.


2020 ◽  
Vol 72 (5) ◽  
Author(s):  
Mario Fadin ◽  
Maria C. Nicoletti ◽  
Marzia Pellizzato ◽  
Manuela Accardi ◽  
Maria G. Baietti ◽  
...  
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document